Collectionner le produit
Détails du produit
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureBinding Capacity>137 pmol (20μg) Anti-VEGF antibody/mg beads>137 pmol (20 μg) Anti-VEGF antibody/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
Product Description
The Human VEGF165-coupled Magnetic Beads is produced by coupling biotinylated human VEGF165 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-VEGF165 antibody or VEGFR2/KDR protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
Assay Principles
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Typical Data
Immobilized 31.6 μg VEGF165 protein/1mg beads can bind Anti-VEGF Antibody with an EC50 of 0.7726 μg/mL.
Protocol
Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Protocol
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unfree-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
Protocol
Avis des utilisateurs Publier un commentaire
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Vascular endothelial growth factor A
- Catégorie：
- Nombre de médicaments répertoriés：
54 Détails
- Nombre de médicaments cliniques：
61 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
